Inthera Bioscience has secured 4.7 million francs in the second tranche of its financing round. It therefore concludes the Series A financing with 9.6 million francs in total.
The startup’s proprietary technology platform identifies molecules that can influence intracellular protein-protein interactions in a targeted way. Inthera Bioscience aims to employ the platform to develop drug candidates for the treatment of cancer, with a particular focus on solid tumours.
“Securing the milestone driven second tranche of our Series A financing represents the validation that our platform can deliver drug leads targeting specific intracellular protein-protein interactions,” commented CEO Uli Kessler in a press release. The company is well on the way to starting clinical trials with a first oral drug candidate soon.
In addition to the successful financing round, Inthera Bioscience also announced that its management team is expanding. Bernd Hentsch is joining the company as Chief Development Officer, having previously worked at the German companies 4SC AG and Merck KGaA. Ralph Lindemann, who joins Inthera Bioscience from Merck KGaA, will be Chief Scientific Officer. Finally, Monique Schiersing has been selected as the new Chief Operating Officer of Inthera Bioscience. Her prior roles included Investment Director at the Roche Venture Fund.
Inthera Bioscience was founded in 2013 and has its headquarters in Wädenswil.
More News
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space